03 October 2023
03 October 2023
The Physiology and Medicine Prize has gone to two researchers whose work laid the foundation for Pfizer and Moderna’s Covid-19 vaccines.
The company will offload its API and women’s healthcare businesses for $1.2bn.
The approval was based on data from the Phase II PHYOX 2 study and interim data from the ongoing PHYOX 3 extension trial.
Biogen’s Tofidence has secured FDA approval for all arthritis indications similar to Roche’s Actemra.
The device allows patients to administer their therapy subcutaneously from home or in the clinic to increase flexibility in their daily lives.
Novartis unveiled positive top-line Phase III results for iptacopan in IgA nephropathy and plans talks with the FDA to obtain accelerated approval in 2024.
An NDA submission for EryDex is currently intended for Q4 2025, assuming positive Phase III study results.
The pharma company is seeking US approval of the drug for three bacterial diseases, with a PDUFA date of 3 April 2024.
The Excellence Awards celebrate the greatest achievements and innovations in the industry, and the people and companies that are driving change.
With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.
Give your business an edge with our leading industry insights.
